Labcorp (LH) FY2024 10-K Annual Report
Labcorp (LH) 10-K annual report for fiscal year 2024, filed with SEC EDGAR on Feb 25, 2025. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Labcorp FY2024 10-K Analysis
Business Overview
- • Core business model: Global comprehensive laboratory services providing diagnostic and drug development insights to healthcare and pharmaceutical clients across ~100 countries
- • New holding company structure implemented May 17, 2024, establishing Labcorp Holdings Inc. as successor issuer with no independent operations
- • Spin-off of Fortrea Holdings Inc. completed June 30, 2023, separating Clinical Development and Commercialization Services, refocusing remaining drug development operations into Biopharma Laboratory Services segment
- • Revenue growth to $13.0B in 2024 from $12.2B in 2023, with Labcorp Diagnostics contributing 78% and Biopharma Laboratory Services 22% of revenues in 2024
- • Cash and cash equivalents surged to $1.52B at year-end 2024 from $537M in 2023, reflecting significant liquidity improvement
Management Discussion & Analysis
- • Revenue $13,008.9M, up 7.0% YoY from $12,161.6M; Dx segment $10,144.3M up 7.7%, BLS $2,922.6M up 5.3%
- • Operating margin Dx 15.8% vs 16.9% (-1.1%), BLS 15.7% vs 14.3% (+1.4%)
- • Best segment BLS operating income $458.9M up 15.8%, worst Dx $1,606.3M up 0.9% with margin decline
- • Cash flow from operations $1,585.8M up $383.5M; Capex $489.9M (3.8% of revenue); Dividends $243.1M; Share repurchases $250.1M
- • 2025 Capex guidance similar to 2024 for growth, facility expansion, LaunchPad, acquisition integration; Risks include economic changes, customer delays, increased costs impacting goodwill valuation
Risk Factors
- • Litigation risk from 2019 AMCA data breach involving patient info, triggering ongoing regulatory inquiries and legal threats
- • Cybersecurity vulnerability with ransomware incident in 2018 disrupting Dx IT systems and company-wide operations temporarily
- • Dependence on CITO and CIRO leadership with 15+ and 30+ years IT experience for cybersecurity risk management and incident response
- • No specific regulatory law or geopolitical macroeconomic risk detailed in provided text
- • No named competitor or market disruption risk identified in provided text
Labcorp FY2024 Key Financial MetricsXBRL
Revenue
$13.0B
▲ +7.0% YoY
Net Income
$746M
▲ +78.5% YoY
Gross Margin
27.9%
▲ +19bp YoY
Operating Margin
8.4%
▲ +239bp YoY
Net Margin
5.7%
▲ +230bp YoY
ROE
9.3%
▲ +396bp YoY
Total Assets
$18.4B
▲ +9.9% YoY
EPS (Diluted)
$8.84
▲ +85.3% YoY
Operating Cash Flow
$1.6B
▲ +19.4% YoY
Source: XBRL data from Labcorp FY2024 10-K filing on SEC EDGAR. All figures in USD.
Other Labcorp Annual Reports
Get deeper insights on Labcorp
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.